AstraZeneca’s Rare Disease Drug Misses Main Goal in Late-Stage Trial

Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

AstraZeneca’s Ultomiris phase 3 failure boosts Omeros shares and eases competition for Yartemlea in TA-TMA. Read more here.

AstraZeneca’s rare disease drug Ultomiris misses main goal in late-stage trial

AstraZeneca said on Monday its rare disease drug Ultomiris ​failed a late-stage trial in patients with a blood ‌vessel complication following a stem cell transplant, ​the latest in a series of ⁠setbacks this year that have fuelled concerns about the drugmaker’s pipeline.

AstraZeneca reports Phase III results for Ultomiris and Sone-Ve

AstraZeneca has released findings from two Phase III studies, reporting outcomes for Ultomiris in thrombotic microangiopathy following HSCT-TMA and Sone-Ve in advanced gastric and GEJ cancers.The post AstraZeneca reports Phase III results for Ultomiris and Sone-Ve appeared first on Hospital Management.

AstraZeneca's HSCT-TMA drug misses main endpoint

AstraZeneca's ravulizumab missed its main goal in an adult HSCT-TMA trial, though paediatric survival data showed promise.

Updated: AstraZeneca sees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease

AstraZeneca said Monday that a key late-stage trial of its Claudin 18.2-targeting ADC in stomach cancer had succeeded, albeit with a caveat — but another Phase 3 trial of Ultomiris yielded subpar results in a rare ...